NR ADVN
AU Evatt,B.L.
TI Prions and haemophilia: assessment of risk.
QU Haemophilia 1998 Jul; 4(4): 628-33
PT journal article; review; review, tutorial
AB Based on information accumulated to date, it is still difficult to assess the risk of Creutzfeldt-Jakob disease (CJD) and blood transfusion with any degree of confidence. However, it is reasonable to conclude that CJD is produced by a transmittable agent which is probably contained in low titer in the blood of infected people and animals. From the present clinical and epidemiological studies, transmission by blood or blood products appears to be a rare or non-existent cause of current and past cases of CJD in humans. Since blood products are necessary to prevent the immediate risk of death or significant morbidity in many clinical conditions, therapeutic decisions should be made after consideration of the known risk in these situations vs the theoretical long-term risk of the rare occurrence of CJD.
IN Der Autor oder die Autorin hält es für vernünftig, bei Creutzfeldt-Jakob-Patienten eine wenn auch geringe Infektiosität von Blut zu vermuten. Da aber die bislang zu Verfügung stehenden epidemiologischen Daten höchstens für einen geringen Einfluß dieses potentiellen Infektionsweges auf die bis jetzt untersuchten Fälle von Creutzfeldt-Jakob-Krankheit sprechen und gleichzeitig Blutprodukte in vielen akuten Fällen lebenswichtig sind, sollte das theoretische Langzeitrisiko einer CJD-Übertragung gegen den unmittelbaren Nutzen der Anwedung von Blutprodukten abgewogen werden.
ZR 42
MH Animal; Blood Coagulation Factors/*adverse effects/therapeutic use; Blood Transfusion/*adverse effects; Cattle; Creutzfeldt-Jakob Syndrome/*transmission; Drug Contamination; Encephalopathy, Bovine Spongiform/transmission; Hemophilia A/*therapy; Human; Risk
AD Hematologic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. ble1@cdc.gov
SP englisch
PO England